Free Trial
→ Elon just did WHAT!? (From Brownstone Research) (Ad) Buy GPCR Stock  Free GPCR Stock Alerts

Structure Therapeutics (GPCR) Financials

Structure Therapeutics logo
$26.00 +0.67 (+2.63%)
As of 02:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Structure Therapeutics

Annual Income Statements for Structure Therapeutics

This table shows Structure Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -53 -89 -122
Consolidated Net Income / (Loss)		 -51 -90 -123
Net Income / (Loss) Continuing Operations		 -51 -90 -123
Total Pre-Tax Income 		-51 -89 -122
Total Operating Income		 -53 -103 -158
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 53 103 158
Selling, General & Admin Expense		 16 33 49
Research & Development Expense		 36 70 109
Total Other Income / (Expense), net		 1.26 13 36
Interest Expense		 -1.26 -13 -36
Income Tax Expense		 0.02 0.24 0.31
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - -0.63 -0.39
Basic Earnings per Share		 ($5.51) ($0.81) ($0.78)
Weighted Average Basic Shares Outstanding		 9.58M 110.20M 157.92M
Diluted Earnings per Share		 ($5.51) ($0.81) ($0.78)
Weighted Average Diluted Shares Outstanding		 9.58M 110.20M 157.92M
Weighted Average Basic & Diluted Shares Outstanding		 - 139.79M 172.03M

Quarterly Income Statements for Structure Therapeutics

This table shows Structure Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -12 -12 -18 -23 -24 -24 -26 -26 -31 -39
Consolidated Net Income / (Loss)		 -12 -12 -18 -23 -24 -25 -26 -26 -34 -36
Net Income / (Loss) Continuing Operations		 -12 -12 -18 -23 -24 -25 -26 -26 -34 -36
Total Pre-Tax Income 		-12 -12 -18 -23 -23 -25 -26 -26 -34 -36
Total Operating Income		 -13 -13 -20 -26 -26 -31 -32 -33 -46 -47
Total Operating Expenses		 13 13 20 26 26 31 32 33 46 47
Selling, General & Admin Expense		 3.53 4.60 6.51 6.58 8.63 11 11 11 13 14
Research & Development Expense		 9.16 8.36 13 19 18 20 21 22 33 33
Total Other Income / (Expense), net		 0.35 0.90 1.70 2.83 2.69 6.18 6.01 7.34 12 11
Interest Expense		 -0.35 -0.90 -1.70 -2.83 -2.69 -6.18 -6.01 -7.34 -12 -11
Income Tax Expense		 0.07 -0.18 0.03 0.12 0.41 -0.31 0.03 0.05 0.09 0.14
Basic Earnings per Share		 ($1.27) ($1.16) ($0.25) ($0.20) ($0.21) ($0.15) ($0.19) ($0.18) ($0.20) ($0.21)
Weighted Average Basic Shares Outstanding		 9.78M 9.58M 71.66M 114.76M 114.95M 110.20M 139.71M 148.24M 171.63M 157.92M
Diluted Earnings per Share		 ($1.27) ($1.16) ($0.25) ($0.20) ($0.21) ($0.15) ($0.19) ($0.18) ($0.20) ($0.21)
Weighted Average Diluted Shares Outstanding		 9.78M 9.58M 71.66M 114.76M 114.95M 110.20M 139.71M 148.24M 171.63M 157.92M
Weighted Average Basic & Diluted Shares Outstanding		 - 0.00 114.80M 114.81M 139.16M 139.79M 139.86M 171.59M 171.78M 172.03M

Annual Cash Flow Statements for Structure Therapeutics

This table details how cash moves in and out of Structure Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -79 104 40
Net Cash From Operating Activities		 -46 -79 -117
Net Cash From Continuing Operating Activities		 -46 -79 -117
Net Income / (Loss) Continuing Operations		 -51 -90 -123
Consolidated Net Income / (Loss)		 -51 -90 -123
Depreciation Expense		 0.28 0.30 0.99
Amortization Expense		 -0.91 -5.98 -18
Non-Cash Adjustments To Reconcile Net Income		 2.86 8.85 20
Changes in Operating Assets and Liabilities, net		 2.97 7.24 2.96
Net Cash From Investing Activities		 -62 -268 -359
Net Cash From Continuing Investing Activities		 -62 -268 -359
Purchase of Property, Plant & Equipment		 -0.16 -2.17 -1.29
Purchase of Investments		 -123 -417 -703
Sale and/or Maturity of Investments		 62 151 345
Net Cash From Financing Activities		 29 452 515
Net Cash From Continuing Financing Activities		 29 452 515
Repayment of Debt		 - -22 -1.80
Issuance of Common Equity		 0.00 472 515
Other Financing Activities, net		 0.03 0.80 1.85

Quarterly Cash Flow Statements for Structure Therapeutics

This table details how cash moves in and out of Structure Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -27 -2.00 100 -86 10 79 -32 284 -209 -2.62
Net Cash From Operating Activities		 -10 -12 -20 -17 -21 -22 -34 -26 -20 -36
Net Cash From Continuing Operating Activities		 -10 -12 -20 -17 -20 -22 -34 -26 -20 -36
Net Income / (Loss) Continuing Operations		 -12 -12 -18 -23 -24 -25 -26 -26 -34 -36
Consolidated Net Income / (Loss)		 -12 -12 -18 -23 -24 -25 -26 -26 -34 -36
Depreciation Expense		 0.08 0.07 0.07 0.07 0.08 0.07 0.22 0.23 0.27 0.27
Amortization Expense		 -0.28 -0.48 -0.35 -1.64 -1.66 -2.32 -3.28 -3.18 -5.98 -6.03
Non-Cash Adjustments To Reconcile Net Income		 0.72 0.70 2.62 1.79 2.13 2.31 3.18 3.85 7.07 6.30
Changes in Operating Assets and Liabilities, net		 1.42 -0.44 -4.67 6.17 3.03 2.72 -8.17 -1.26 13 -0.53
Net Cash From Investing Activities		 -17 10 -49 -69 30 -181 1.42 -205 -189 33
Net Cash From Continuing Investing Activities		 -17 10 -49 -69 30 -181 1.42 -205 -189 33
Purchase of Property, Plant & Equipment		 -0.07 -0.07 0.00 -0.19 -0.82 -1.16 -0.16 -0.43 -0.69 -0.02
Purchase of Investments		 -46 -9.19 -190 24 -15 -237 -32 -284 -255 -132
Sale and/or Maturity of Investments		 29 20 141 -93 46 57 34 80 66 166
Net Cash From Financing Activities		 -0.26 -0.32 170 -0.30 0.47 282 0.70 515 -0.76 0.62
Net Cash From Continuing Financing Activities		 -0.26 -0.32 170 -0.30 0.47 282 0.70 515 -0.76 0.62
Issuance of Common Equity		 - - 172 - - 300 0.00 515 - 0.39
Other Financing Activities, net		 0.03 - 0.03 0.18 0.47 0.12 0.76 0.48 0.40 0.22

Annual Balance Sheets for Structure Therapeutics

This table presents Structure Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 98 482 903
Total Current Assets		 93 474 891
Cash & Equivalents		 26 130 170
Short-Term Investments		 65 338 714
Prepaid Expenses		 2.25 6.29 7.69
Plant, Property, & Equipment, net		 1.03 3.23 3.48
Total Noncurrent Assets		 3.73 5.18 8.64
Other Noncurrent Operating Assets		 3.73 5.18 8.64
Total Liabilities & Shareholders' Equity		 98 482 903
Total Liabilities		 13 29 38
Total Current Liabilities		 13 25 36
Accounts Payable		 6.01 4.74 8.02
Accrued Expenses		 6.74 19 26
Other Current Liabilities		 0.26 1.44 1.70
Total Noncurrent Liabilities		 0.00 4.31 2.47
Other Noncurrent Operating Liabilities		 0.00 4.31 2.47
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -115 453 865
Total Preferred & Common Equity		 -115 453 865
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 -115 453 865
Common Stock		 1.92 659 1,193
Retained Earnings		 -117 -207 -329
Accumulated Other Comprehensive Income / (Loss)		 -0.11 0.52 0.91

Quarterly Balance Sheets for Structure Therapeutics

This table presents Structure Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 247 229 216 457 947 933
Total Current Assets		 246 228 210 449 938 924
Cash & Equivalents		 126 41 51 98 382 172
Short-Term Investments		 114 184 155 339 545 743
Prepaid Expenses		 5.29 3.64 4.54 13 11 8.37
Plant, Property, & Equipment, net		 0.96 1.08 2.41 3.12 3.32 3.74
Total Noncurrent Assets		 0.24 0.13 4.00 4.75 6.09 5.83
Other Noncurrent Operating Assets		 0.24 0.13 4.00 4.75 6.09 5.83
Total Liabilities & Shareholders' Equity		 247 229 216 457 947 933
Total Liabilities		 11 15 23 27 26 36
Total Current Liabilities		 11 15 20 24 23 33
Accounts Payable		 4.95 5.70 3.32 6.54 2.21 8.45
Accrued Expenses		 5.89 9.24 16 15 19 23
Other Current Liabilities		 0.17 0.07 0.82 1.60 1.63 1.71
Total Noncurrent Liabilities		 0.00 0.00 3.32 3.82 3.34 2.98
Other Noncurrent Operating Liabilities		 - - 3.32 3.82 3.34 2.98
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 236 214 193 430 921 897
Total Preferred & Common Equity		 236 214 193 430 921 897
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 236 214 193 430 921 897
Common Stock		 371 373 375 663 1,180 1,187
Retained Earnings		 -135 -158 -182 -233 -259 -293
Accumulated Other Comprehensive Income / (Loss)		 0.15 -0.39 -0.31 -0.09 -0.49 2.84

Annual Metrics and Ratios for Structure Therapeutics

This table displays calculated financial ratios and metrics derived from Structure Therapeutics' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -103.90% -62.00%
EBIT Growth		 0.00% -95.53% -53.96%
NOPAT Growth		 0.00% -95.53% -53.96%
Net Income Growth		 0.00% -74.63% -36.72%
EPS Growth		 0.00% 85.30% 3.70%
Operating Cash Flow Growth		 0.00% -72.35% -46.73%
Free Cash Flow Firm Growth		 0.00% 0.00% -67.38%
Invested Capital Growth		 0.00% -139.04% -30.08%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -22.45% -12.53%
EBIT Q/Q Growth		 0.00% -21.29% -11.30%
NOPAT Q/Q Growth		 0.00% -21.29% -11.30%
Net Income Q/Q Growth		 0.00% -16.40% -10.83%
EPS Q/Q Growth		 0.00% 55.49% -8.33%
Operating Cash Flow Q/Q Growth		 0.00% -13.90% -14.46%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -13.86%
Invested Capital Q/Q Growth		 0.00% -15.22% -1.03%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.03% 100.26% 100.25%
Interest Burden Percent		 97.61% 86.97% 77.24%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -60.50% -33.33% -18.60%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 82.11% -20.94% -18.60%
Return on Equity Simple (ROE_SIMPLE)		 44.57% -19.79% -14.17%
Net Operating Profit after Tax (NOPAT)		 -37 -72 -111
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -15.99% -6.33% -1.74%
Return On Investment Capital (ROIC_SIMPLE)		 - -15.88% -12.81%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -53 -103 -158
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -53 -108 -176
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 9.92 4.95
Price to Tangible Book Value (P/TBV)		 0.00 9.92 4.95
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.07 -1.04 -1.03
Leverage Ratio		 1.15 1.08 1.05
Compound Leverage Factor		 1.13 0.94 0.81
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 235.72% 0.00% 0.00%
Common Equity to Total Capital		 -135.72% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 4.97 92.58 66.82
Noncontrolling Interest Sharing Ratio		 235.72% 37.18% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 7.16 19.14 24.74
Quick Ratio		 6.98 18.89 24.53
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -64 -106
Operating Cash Flow to CapEx		 -29,754.84% -3,668.11% -9,041.55%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -6.01 -14 -19
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -8.35 -4.32
Enterprise Value (EV)		 270 4,024 3,399
Market Capitalization		 161 4,492 4,283
Book Value per Share		 ($12.01) $3.26 $5.03
Tangible Book Value per Share		 ($12.01) $3.26 $5.03
Total Capital		 85 453 865
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -91 -467 -884
Capital Expenditures (CapEx)		 0.16 2.17 1.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -18 -28
Debt-free Net Working Capital (DFNWC)		 80 449 855
Net Working Capital (NWC)		 80 449 855
Net Nonoperating Expense (NNE)		 15 18 12
Net Nonoperating Obligations (NNO)		 -91 -467 -884
Total Depreciation and Amortization (D&A)		 -0.63 -5.68 -17
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.81) ($0.78)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 110.20M 157.92M
Adjusted Diluted Earnings per Share		 $0.00 ($0.81) ($0.78)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 110.20M 157.92M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 139.79M 172.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -37 -72 -111
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -4.91% 0.00% 0.00%

Quarterly Metrics and Ratios for Structure Therapeutics

This table displays calculated financial ratios and metrics derived from Structure Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 0.00% -54.67% -98.24% -114.99% -148.81% -76.01% -31.61% -85.92% -58.86%
EBIT Growth		 0.00% 0.00% -51.71% -86.15% -105.98% -139.23% -62.93% -28.20% -75.31% -51.84%
NOPAT Growth		 0.00% 0.00% -51.71% -86.15% -105.98% -139.23% -62.93% -28.20% -75.31% -51.84%
Net Income Growth		 0.00% 0.00% -37.41% -66.91% -92.17% -106.34% -44.85% -11.83% -42.39% -48.88%
EPS Growth		 0.00% 0.00% 82.64% 87.80% 83.46% 87.07% 24.00% 10.00% 4.76% -40.00%
Operating Cash Flow Growth		 0.00% 0.00% -50.23% -67.35% -96.14% -80.68% -67.82% -56.23% 4.19% -67.83%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -119.52% -241.77% -346.12% -114.50%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -139.04% -47.00% 40.16% -48.35% -30.08%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 7.22% -3.61% -49.12% -38.30% -0.62% -19.90% -5.49% -3.42% -42.14% -2.45%
EBIT Q/Q Growth		 9.08% -2.07% -51.66% -32.26% -0.61% -18.55% -3.29% -4.06% -37.58% -2.67%
NOPAT Q/Q Growth		 9.08% -2.07% -51.66% -32.26% -0.61% -18.55% -3.29% -4.06% -37.58% -2.67%
Net Income Q/Q Growth		 10.98% 4.37% -51.37% -29.51% -2.50% -2.69% -6.26% 0.01% -30.51% -7.36%
EPS Q/Q Growth		 22.56% 8.66% 78.45% 20.00% -5.00% 28.57% -26.67% 5.26% -11.11% -5.00%
Operating Cash Flow Q/Q Growth		 -3.82% -14.74% -68.87% 16.81% -21.68% -5.70% -56.84% 22.56% 25.37% -85.15%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 13.25% 27.15% -128.45% -52.05% -35.07% 4.91% -9.84%
Invested Capital Q/Q Growth		 0.00% 0.00% 24.89% -125.49% -22.49% -15.22% 53.81% 8.20% -203.68% -1.03%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.59% 98.51% 100.14% 100.51% 101.73% 98.74% 100.11% 100.20% 100.27% 100.37%
Interest Burden Percent		 97.25% 93.05% 91.35% 89.13% 89.72% 80.06% 81.23% 77.98% 73.93% 77.23%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -60.50% -23.78% -30.57% -39.90% -33.33% -29.33% -17.69% -20.29% -18.60%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 82.11% -23.78% -30.57% -39.90% -20.94% -29.33% -17.69% -20.29% -18.60%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -23.78% -30.57% -39.90% 0.00% -22.73% -10.90% -12.33% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.89 -9.07 -14 -18 -18 -22 -22 -23 -32 -33
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -3.09% -3.50% -4.53% -5.41% -1.01% -1.07% -0.47% -0.34% -0.52%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -4.79% - - - -3.81%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -13 -13 -20 -26 -26 -31 -32 -33 -46 -47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -13 -20 -28 -28 -33 -35 -36 -52 -53
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 7.21 22.25 30.04 9.92 13.93 6.32 8.40 4.95
Price to Tangible Book Value (P/TBV)		 0.00 0.00 7.21 22.25 30.04 9.92 13.93 6.32 8.40 4.95
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.07 -1.02 -1.05 -1.06 -1.04 -1.02 -1.01 -1.03 -1.03
Leverage Ratio		 0.00 1.15 1.05 1.07 1.12 1.08 1.06 1.04 1.05 1.05
Compound Leverage Factor		 0.00 1.07 0.96 0.95 1.01 0.86 0.86 0.81 0.78 0.81
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 235.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -135.72% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 6.30 93.08 190.43 148.05 93.07 131.26 135.02 124.66 67.22
Noncontrolling Interest Sharing Ratio		 0.00% 235.72% 0.00% 0.00% 0.00% 37.18% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 7.16 22.37 15.20 10.45 19.14 19.05 41.38 27.63 24.74
Quick Ratio		 0.00 6.98 21.89 14.96 10.22 18.89 18.50 40.92 27.38 24.53
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 -9.24 -8.02 -5.84 -13 -20 -27 -26 -29
Operating Cash Flow to CapEx		 -14,556.94% -16,938.03% 0.00% -8,845.03% -2,506.95% -1,879.67% -21,037.04% -6,181.03% -2,875.33% -227,918.75%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -6.01 -4.51 -10 -12 -14 -6.63 -6.09 -18 -19
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 -4.51 -10 -12 -8.35 -2.12 4.09 -6.03 -4.32
Enterprise Value (EV)		 0.00 270 1,464 4,546 5,590 4,024 5,552 4,894 6,618 3,399
Market Capitalization		 161 161 1,705 4,771 5,796 4,492 5,988 5,821 7,533 4,283
Book Value per Share		 $0.00 ($12.01) $3.30 $1.87 $1.68 $3.26 $3.07 $6.59 $5.23 $5.03
Tangible Book Value per Share		 $0.00 ($12.01) $3.30 $1.87 $1.68 $3.26 $3.07 $6.59 $5.23 $5.03
Total Capital		 0.00 85 236 214 193 453 430 921 897 865
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -91 -241 -225 -205 -467 -436 -927 -915 -884
Capital Expenditures (CapEx)		 0.07 0.07 0.00 0.19 0.82 1.16 0.16 0.43 0.69 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -11 -5.71 -11 -16 -18 -11 -12 -25 -28
Debt-free Net Working Capital (DFNWC)		 0.00 80 235 213 190 449 426 915 890 855
Net Working Capital (NWC)		 0.00 80 235 213 190 449 426 915 890 855
Net Nonoperating Expense (NNE)		 3.53 2.81 4.22 5.09 5.56 2.81 3.63 2.71 1.89 3.54
Net Nonoperating Obligations (NNO)		 0.00 -91 -241 -225 -205 -467 -436 -927 -915 -884
Total Depreciation and Amortization (D&A)		 -0.20 -0.41 -0.28 -1.57 -1.58 -2.25 -3.06 -2.95 -5.71 -5.75
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.16) ($0.25) $0.00 ($0.21) ($0.15) ($0.19) ($0.18) ($0.20) ($0.21)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 9.58M 71.66M 0.00 114.95M 110.20M 139.71M 148.24M 171.63M 157.92M
Adjusted Diluted Earnings per Share		 $0.00 ($1.16) ($0.25) $0.00 ($0.21) ($0.15) ($0.19) ($0.18) ($0.20) ($0.21)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 9.58M 71.66M 0.00 114.95M 110.20M 139.71M 148.24M 171.63M 157.92M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 114.80M 0.00 139.16M 139.79M 139.86M 171.59M 171.78M 172.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.89 -9.07 -14 -18 -18 -22 -22 -23 -32 -33
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -4.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Structure Therapeutics' Financials

When does Structure Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Structure Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Structure Therapeutics' net income changed over the last 2 years?

Structure Therapeutics' net income appears to be on an upward trend, with a most recent value of -$122.53 million in 2024, rising from -$51.32 million in 2022. The previous period was -$89.62 million in 2023. See Structure Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Structure Therapeutics's operating income?
Structure Therapeutics's total operating income in 2024 was -$158.23 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $158.23 million
How has Structure Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Structure Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Structure Therapeutics have?

Structure Therapeutics' total liabilities were at $38.49 million at the end of 2024, a 32.5% increase from 2023, and a 195.8% increase since 2022.

How much cash does Structure Therapeutics have?

In the past 2 years, Structure Therapeutics' cash and equivalents has ranged from $26.09 million in 2022 to $169.51 million in 2024, and is currently $169.51 million as of their latest financial filing in 2024.

How has Structure Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Structure Therapeutics' book value per share changed from -12.01 in 2022 to 5.03 in 2024, a change of -141.9%.


Related Companies

This page (NASDAQ:GPCR) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
Your Wealth is Being Erased – Save It Before It’s Gone Forever
What If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...
Hamilton Gold Group | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...
Brownstone Research | Sponsored